ImClone Systems Inc (formerly IMCL)

[biophud]

Comments regarding recent Yahoo postings on 11F8 and humanized c225. Corky mentioned that 11F8 and humanized C225 are not the same thing. I think that this is an important point that raises several questions. Specifically how are these two molecules treated in terms of intellectual property? and how are these two entities treated in terms of IMCL's contractual agrements?

IMCL has a patent on a CDR-grafted humanized c225. See below.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PTXT&s1=imclone.ASNM.&OS=AN/imclone&RS=AN/imclone

As far as I know IMCL does not have a clinical trial with a CDR-grafted humanized c225 antibody

11F8 is a fully human phage-derived antibody derived from DYAX's phage library technology.

As far as I know IMCL does not have a patent on a fully human phage-derived anti EGFR-antibody.

Comments appreciated,

biophud